New Delhi (PTI); Congress leader Jairam Ramesh on Friday claimed there is no documented evidence of Lord Mountbatten, C Rajagopalachari and Jawaharlal Nehru describing the 'Sengol' as a symbol of transfer of power by the British to India.

He also alleged that Prime Minister Narendra Modi and his drum-beaters are using the ceremonial sceptre for their political ends in Tamil Nadu.

The 'Sengol' will be installed close to the Chair of the Lok Sabha speaker after the new Parliament building is inaugurated by Modi on May 28, an event 20 Opposition parties, including the Congress, are boycotting.

On Thursday, the BJP had alleged that the Congress displayed disregard for Hindu traditions by calling the sacred 'Sengol' a "golden stick gifted" to India's first prime minister Nehru and tucking it away in a museum.

The vesting of the "sacred 'Sengol'" with Nehru, on the eve of India's Independence, was the exact moment of transfer of power from the British to India, BJP leader Amit Malviya had said.

On Twitter, Ramesh said, "The sceptre is now being used by the PM (prime minister) and his drum-beaters for their political ends in Tamil Nadu. This is typical of this brigade that embroiders facts to suit its twisted objectives. The real question is why is President Droupadi Murmu not being allowed to inaugurate the new Parliament."

He claimed that a majestic sceptre conceived of by a religious establishment in the Madras province and crafted in Madras city (now Chennai) was indeed presented to Nehru in August 1947.

"There is no documented evidence whatsoever of Mountbatten, Rajaji and Nehru describing this sceptre as a symbol of transfer of British power to India. All claims to this effect are plain and simple -- bodgus," he said.

"Wholly and completely manufactured in the minds of a few and dispersed into WhatsApp, and now to the drum-beaters in the media. Two of the finest Rajaji scholars with impeccable credentials have expressed surprise," the Congress general secretary communications said.

While announcing the boycott, the Opposition parties had said the prime minister's decision to inaugurate it by himself, "completely sidelining President Droupadi Murmu, is not only a grave insult but a direct assault on our democracy which demands a commensurate response".

"Is it any surprise that the new Parliament is being consecrated with typically false narratives from WhatsApp University? The BJP-RSS distorians stand exposed yet again with maximum claims, minimum evidence," Congress general secretary communications Ramesh said in his tweet.

He said the sceptre presented to Nehru was later kept for display at the Allahabad Museum. What Nehru said there on December 14, 1947 is a matter of public record despite whatever labels may say, Ramesh said.

Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.



New Delhi (PTI): Expanding the scope of its hearing in the Patanjali Ayurved case, the Supreme Court on Tuesday took a stern view of misleading advertisements by FMCG firms and asked three Union ministries to inform it about the steps they have taken to curb the practice which takes "public for a ride" and adversely affects their health.

The court passed the order after Yoga guru Ramdev and his aide Balkrishna of Patanjali Ayurved Ltd. told a bench of Justices Hima Kohli and Ahsanuddin Amanullah that they have issued unqualified public apology in as many as 67 newspapers over misleading advertisements and are willing to issue additional advertisements expressing their contrition.

The bench said the public apology published in newspapers were not on record and asked those to be filed within two days. It posted the matter for April 30 for further consideration.

While hearing the Patanjali case, the apex court said the implementation of the relevant provisions of the Drugs and Magic Remedies (Objectionable Advertisements) Act, the Drugs and Cosmetics Act and the Consumer Protection Act and the related rules also needed a closer examination.

It said the issue was not limited to Patanjali but extended to all Fast-Moving Consumer Goods (FMCG) firms which have been issuing "misleading advertisements and taking the public for a ride, in particular affecting the health of babies, school-going children and senior citizens who have been consuming products on the basis of the said misrepresentation".

"We must clarify that we are not here to gun for a particular party or a particular agency or a particular authority. This is a PIL, and in the larger interest of the consumers, public should know which way they are going and how and why they can be misled, and how authorities are acting to prevent it," the bench said.

The court asked the Union ministries of consumer affairs, information and broadcasting, and information technology to explain what action they have taken to prevent the misuse of consumer laws.

It also sought an explanation from the Centre over an August 2023 letter issued by the Ministry of Ayush to the licencing authorities of all states and Union Territories and drug controllers of Ayush asking them to not initiate any action under rule 170 of Drugs and Cosmetics Rules, 1945.

The bench also asked the Indian Medical Association (IMA), the petitioner in the Patanjali advertisements case, to "put its house in order".

It said several complaints have been made about alleged unethical acts by members of the IMA who prescribe highly expensive medicines and line of treatment. The bench also ordered impleading the National Medical Commission (NMC) as a respondent in the matter for effective assistance to the court.

At the outset, senior advocate Mukul Rohatgi, appearing for Ramdev and Patanjali Ayurved Ltd managing director Balkrishna, told the bench they have issued on Monday unqualified apology for the "lapses" on their part.

"Where? Why it is not filed?" the bench asked.

Rohatgi said it was issued on Monday in 67 newspapers across the country.

When the court asked the senior advocate why did the respondents wait for a whole week before publishing the public apology, Rohatgi said, "Its language had to be changed".

The court also quizzed him about the size of advertisements.

"Is it the same size of advertisements that you normally issue in newspapers?" it asked Rohatgi, who submitted "It costs tens of lakhs (of rupees)".

The bench ordered that the apology published be filed on record and added it wanted to see the actual advertisement published in newspapers.

"The said advertisements are not on record. It is submitted that the same have been collated and shall be filed in the course of the day with copies to counsel for the parties. Needful shall be done within two days with copies to counsel for the parties," it said.

The counsel said additional advertisement shall be issued by Ramdev and Balkrishna tendering unqualified apology for the lapses on their part.

The bench said it was necessary to implead the three central ministries in order to examine the steps taken to prevent the abuse of the Drugs and Magic Remedies (Objectionable Advertisements) Act and rules, the Drugs and Cosmetics Act and the Consumer Protection Act.

It said these ministries shall file affidavits enunciating the action they have taken to prevent the misuse/abuse of these statutes along with the relevant data since 2018.

The bench said licencing authorities of all states and UTs shall also be impleaded as co-respondents in the matter.

The bench told the IMA's counsel that while they are pointing fingers at Patanjali, "the other four fingers are also pointing at you (IMA)".

On April 16, the apex court had warned Ramdev and Balkrishna against any attempt to "degrade allopathy" and permitted them to tender a "public apology and show contrition" within a week in the contempt proceedings in the misleading advertisements case against Patanjali Ayurved Ltd.

The apex court is hearing a plea filed in 2022 by the IMA alleging a smear campaign against the Covid vaccination drive and modern systems of medicine.

Ramdev and Balkrishna had earlier tendered an "unconditional and unqualified apology" before the top court over advertisements issued by the firm making tall claims about the medicinal efficacy of its products